TSXV:SMY
TSXV:SMYMetals and Mining

TSX Penny Stocks To Watch In January 2026

The first week of 2026 has been marked by significant economic data releases and geopolitical developments, including U.S. military actions in Venezuela and labor-market updates from both the U.S. and Canada. Amid these broader market conditions, investors often look for opportunities that offer growth potential without breaking the bank. Penny stocks, despite their somewhat outdated name, continue to attract attention as they can provide affordability and potential upside when supported by...
TSE:6645
TSE:6645Electronic

Assessing OMRON (TSE:6645) Valuation After Recent Share Price Moves And Longer Term Return Declines

OMRON (TSE:6645) has drawn fresh attention after recent share price moves, leaving investors weighing its current valuation against mixed return figures over the past year and over a multiyear period. See our latest analysis for OMRON. At a share price of ¥4,043, OMRON has seen a 2.28% 1 month share price return and a 1.18% year to date share price return. However, the 1 year, 3 year, and 5 year total shareholder returns of 14.97%, 37.02%, and 54.29% declines suggest recent momentum is modest...
ENXTAM:ASML
ENXTAM:ASMLSemiconductor

Is ASML Holding (ENXTAM:ASML) Pricing In Its Chip Supply Chain Importance Too Fully?

If you are wondering whether ASML Holding's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. The stock recently closed at €1,149.40, with returns of 13.5% over 7 days, 26.5% over 30 days, 16.5% year to date, 55.7% over 1 year, 100.1% over 3 years and 155.6% over 5 years. This naturally raises questions about how much optimism is already reflected in the price. Recent news coverage has focused on ASML...
OM:ERIC B
OM:ERIC BCommunications

How Investors Are Reacting To Telefonaktiebolaget LM Ericsson (OM:ERIC B) Cutting 1,600 Swedish Jobs

In January 2026, Ericsson announced proposed staff reductions affecting about 1,600 positions in Sweden as part of global cost-cutting measures to protect its competitiveness and support ongoing investments in high-performing, programmable networks. The move highlights Ericsson’s push to streamline its cost base at home while continuing to fund technology leadership that underpins new monetization opportunities for its telecom customers. We’ll now examine how Ericsson’s Swedish job cuts,...
NYSE:SNOW
NYSE:SNOWIT

Is It Too Late To Consider Snowflake (SNOW) After Recent Share Price Volatility?

If you are wondering whether Snowflake's share price still reflects its long term potential or has run ahead of itself, looking closely at how the stock is valued can help frame your next move. Snowflake recently closed at US$207.74, with returns of 23.9% over 1 year and 53.6% over 3 years, while the last 7, 30 and year to date periods show returns of 7.2%, 5.8% and 4.1% declines respectively. Recent coverage has focused on Snowflake's role in cloud based data platforms and how investor...
NYSE:ALK
NYSE:ALKAirlines

Is Alaska Air Group (ALK) Pricing Justified After Mixed Share Price Performance?

Wondering if Alaska Air Group at around US$49.66 is a bargain or fairly priced today? This article breaks down what the current valuation suggests. The stock is up 2.2% over the last week, though it is down 5.3% over 30 days, 3.6% year to date, and 26.3% over the past year, so recent moves may look quite different depending on your time frame. Recent coverage of Alaska Air Group has focused on its share price performance and how the stock compares with peers within the broader airline...
ASX:CUV
ASX:CUVBiotechs

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology. This step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully. We’ll now explore how advancing the proprietary VLRX-L...
NasdaqGM:CSTL
NasdaqGM:CSTLHealthcare

Castle Biosciences (CSTL) Valuation After Upgraded Guidance And Higher Analyst Growth Expectations

Castle Biosciences (CSTL) kicked off 2026 with fresh guidance pointing to 2025 revenue above US$340 million, supported by double digit growth in core test volumes and closely watched by analysts. See our latest analysis for Castle Biosciences. The stock’s 90 day share price return of 84.06% and 1 year total shareholder return of 62.42% suggest momentum has been building, even though the 5 year total shareholder return of 49.49% is still negative. If Castle Biosciences’ update has you thinking...
NYSE:SPHR
NYSE:SPHREntertainment

Sphere Entertainment (SPHR) Valuation After Live Event Momentum And New Technology Leadership

Event snapshot and why Sphere Entertainment is on investors’ radar Sphere Entertainment (SPHR) is in focus after strong live event momentum around its Wizard of Oz production, fresh sponsorship deals, and the appointment of Felicia Yue as Executive Vice President and Chief Technology Officer for the Sphere division. See our latest analysis for Sphere Entertainment. Sphere Entertainment’s share price has been volatile, with a 10.22% 1 month share price return and a 64.29% 3 month share price...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Is Iovance Biotherapeutics (IOVA) A Potential Opportunity After Multi Year Share Price Slide

If you are wondering whether Iovance Biotherapeutics is a beaten down biotech or a potential value opportunity, its current valuation story is worth taking a closer look at. The share price closed at US$2.22 most recently, and investors have seen a 14.9% decline over 7 days, 1.3% decline over 30 days, an 11.9% decline year to date, and a 61.5% decline over 1 year. This follows a 64.0% decline over 3 years and a 95.3% decline over 5 years. Recent news coverage around Iovance Biotherapeutics...
WBAG:LNZ
WBAG:LNZChemicals

Does Lenzing (WBAG:LNZ) Turning CDP Triple “A” Into Enduring Advantage Redefine Its Equity Story?

Lenzing AG was recently awarded the CDP Triple “A” rating for the fourth time, placing it among just 23 companies worldwide recognized across climate change, forests, and water security. This repeat “Triple A” status underscores how deeply Lenzing’s business model is tied to measurable progress in sustainable raw materials sourcing, energy efficiency, and renewable investments. We’ll now examine how this rare CDP Triple “A” recognition shapes Lenzing’s investment narrative, particularly...
NYSE:VICI
NYSE:VICISpecialized REITs

Is It Time To Reassess VICI Properties (VICI) After Recent Experiential REIT Coverage?

Investors may be wondering whether VICI Properties at around US$28.42 is offering good value right now, or if the easy gains are already behind it. The stock has returned 2.0% over the last 7 days, 0.4% over the last 30 days, 1.0% year to date, 2.7% over 1 year and 40.5% over 5 years, which provides a mix of short term moves and longer term context. Recent news coverage around VICI Properties has focused on its position as a major experiential real estate owner and its role within the US...
NYSE:COF
NYSE:COFConsumer Finance

Is Capital One (COF) Still Fairly Priced After Strong Multi Year Rally And Recent Pullback

If you are wondering whether Capital One Financial's share price still lines up with its fundamentals, this article walks through the key numbers so you can judge the value story for yourself. The stock recently closed at US$236.97, with returns of 27.4% over 1 year and very large gains over 3 and 5 years, even as it has seen a 7.3% decline over 7 days, a 1.9% decline over 30 days, and a 4.4% decline year to date. Recent news coverage has focused on Capital One Financial's role in the...
NYSE:HCA
NYSE:HCAHealthcare

Will HCA’s New Chief Nurse Executive Reframe Its Workforce Strategy And Margin Story (HCA)?

Earlier this week, HCA Healthcare announced that longtime executive and nurse leader Erica Rossitto has been promoted to senior vice president and chief nurse executive, effective February 1, 2026, to oversee the nursing agenda for more than 100,000 nurses across its network. Her appointment places a seasoned insider with deep clinical and operational experience at the center of HCA’s workforce, quality, and care-delivery efforts, an area that has been a key pressure point for hospital...
SEHK:6198
SEHK:6198Infrastructure

Will Gaining Effective Control of Ganglianhai Logistics Change Qingdao Port International's (SEHK:6198) Narrative

Qingdao Port International recently amended its Articles of Association to give its unit Qingdao Port Logistics effective control over Ganglianhai Logistics, allowing the formerly jointly controlled entity to be consolidated as a subsidiary despite each partner still holding 50% equity. This shift in control structure, classified as a connected transaction under Hong Kong Listing Rules without requiring independent shareholder approval, materially reshapes how Ganglianhai’s operations and...
NYSE:XPEV
NYSE:XPEVAuto

Is XPeng (NYSE:XPEV) Attractively Priced After Strong One-Year Share Price Rebound?

If you are wondering whether XPeng's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. XPeng shares last closed at US$20.88, with returns of 1.8% over 7 days, 13.0% over 30 days, 2.2% year to date and 50.5% over 1 year, while the 3 year return is 133.3% and the 5 year return is a 61.6% decline. Recent news coverage around XPeng has highlighted the company as part of the broader electric vehicle sector...
NYSE:SYY
NYSE:SYYConsumer Retailing

Assessing Sysco (SYY) Valuation After Earnings Beat And Stable Operating Margins

Sysco (SYY) shares are in focus after the food distribution company reported Q3 CY2025 results, with revenue in line with expectations, earnings per share above forecasts, and operating margins holding steady. See our latest analysis for Sysco. Sysco's Q3 update comes after a mixed stretch for the stock, with a 1-day share price return of 2.68% and a 7-day share price return of 6.61% contrasting with a slightly negative 90-day share price return of 0.91%. Its 1-year total shareholder return...
NYSE:BEKE
NYSE:BEKEReal Estate

China’s Mortgage Easing and Share Buybacks Might Change The Case For Investing In KE Holdings (BEKE)

The People's Bank of China recently cut the weighted average interest rate on corporate and personal housing loans and lowered the minimum down payment for commercial property mortgages to 30%, a policy shift expected to support real estate activity in China. At the same time, KE Holdings has been actively repurchasing shares without changing its total issued Class A share count, underscoring management’s confidence and disciplined capital management amid shifting property market...
NasdaqGS:ZYME
NasdaqGS:ZYMEBiotechs

A Look At Zymeworks (ZYME) Valuation After Positive HERIZON GEA 01 Trial Results And Royalty Milestone Potential

Zymeworks (ZYME) shares are back in focus after the company reported Phase 3 HERIZON-GEA-01 results for Ziihera in HER2-positive gastroesophageal cancer, paired with sizeable potential milestone and royalty economics tied to future regulatory decisions. See our latest analysis for Zymeworks. The Zymeworks share price, now at US$23.63, has been volatile, with a 28.42% 90 day share price return and a 68.91% 1 year total shareholder return suggesting momentum has been building despite a weaker...
NYSE:FOUR
NYSE:FOURDiversified Financial

Evaluating Shift4 Payments (FOUR) Valuation After Recent Share Price Weakness

Shift4 Payments stock snapshot after recent performance moves Shift4 Payments (FOUR) has been in focus after a mixed stretch for shareholders, with a 1 day decline of about 1.8%, a small slip over the past week, and a roughly 10.8% drop over the past 3 months. See our latest analysis for Shift4 Payments. At a share price of US$65.91, Shift4 Payments has seen short term momentum soften, with a 90 day share price return of a 10.79% decline, while the 1 year total shareholder return of a 38.49%...
TSX:SSRM
TSX:SSRMMetals and Mining

Is SSR Mining's (TSX:SSRM) Hod Maden Push Quietly Redefining Its Future Cash Flow Story?

In recent days, SSR Mining has drawn fresh attention as analysts reiterated supportive views while the company continued advancing its Hod Maden gold-copper project in Türkiye, where it holds a 40% stake and operational control. This combination of analyst optimism and progress on what the company views as a high-margin, low-capital-intensity development asset has sharpened investor focus on SSR Mining’s future cash flow profile. We’ll now examine how continued progress at Hod Maden could...
ASX:PDN
ASX:PDNOil and Gas

How Investors May Respond To Paladin Energy (ASX:PDN) Upcoming Q2 FY26 Results And Investor Call

Paladin Energy recently announced it will release its December 2025 quarterly results and host an investor call on 21 January 2026, with a replay available online for investors and other stakeholders. This scheduled update highlights the company’s emphasis on communicating its operational and financial performance, giving investors a fresh reference point ahead of key project and funding decisions. We’ll now look at how this upcoming quarterly update and investor call could influence...
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

A Look At National Vision Holdings (EYE) Valuation After Strong Recent Share Price Momentum

What recent performance suggests about National Vision Holdings With no single headline event driving attention today, National Vision Holdings (EYE) is drawing interest as its shares sit around $29.43 after sharp 1-year and past 3-month total returns. Over the past week and month, the stock shows returns of 10.27% and 2.90%, while year-to-date and 1-year total returns of 13.41% and 173.77% highlight the recent share price strength. See our latest analysis for National Vision Holdings. The...
NYSE:S
NYSE:SSoftware

Does SentinelOne’s (S) GovCloud Win Quietly Redraw Its Public Sector Competitive Moat?

On January 8, 2026, SentinelOne announced that its AI-powered Singularity Platform achieved GovRAMP Authorization at the High Impact level, validating its compliance with rigorous US government cloud security requirements. This authorization, alongside an extensive roster of US and international certifications, strengthens SentinelOne’s appeal to public sector buyers that prioritize standardized, independently assessed security controls. We’ll now explore how GovRAMP High Impact...